Opiant Pharmaceuticals, Inc.
OPNTDelisted Mar 2, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385508
Opiant Pharmaceuticals, Inc. was delisted on Mar 2, 2023; its insiders filed their last Form 4 on Mar 3, 2023; 37 institutions reported holding it in 13F filings for Q4 2022, worth $43.2M in total; no superinvestor held it.
Holders of 5% or more of OPNT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Opiant Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Opiant Pharmaceuticals, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
5 Schedule 13D and 13G filings on Opiant Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 15, 2023 | Western Standard LLC | 13G/AOld format | – | – | – | SEC |
| Nov 28, 2022 | Western Standard LLC | 13GOld format | – | New | – | SEC |
| Jun 17, 2022 | Crystal Roger | 13D/AOld format | – | – | – | SEC |
| Jun 17, 2022 | Sinclair Michael | 13D/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Renaissance Technologies LLC | 13G/AOld format | – | – | – | SEC |
| Jan 27, 2022 | Wells Fargo & Company | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Radoff Bradley Louis | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Stonepine Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Altium Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Wells Fargo & Company | 13GOld format | – | New | – | SEC |
| Feb 10, 2021 | Renaissance Technologies LLC | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Opiant Pharmaceuticals, Inc. shares.
No Form 144 notices for Opiant Pharmaceuticals, Inc. are on file.